Sinotecan

喜诺替康

Report date: 2022/03/09 09:59:51
NME

Base Information

Drug NameSinotecan
Drug Alias NameSinoteceanYC-8
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Zhengda Tianqing Pharmaceutical Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A